Recent Updates
Recently added Catalysts
MPLT Positive Sentiment

MapLight Therapeutics to Participate in Upcoming Investor Conference

Key Takeaway: MapLight Therapeutics, Inc. has announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14. The management team will present and host one-on-one meetings during the event. The company aims to improve treatments for central nervous system disorders through its innovative discovery platform.

Market Sentiment Analysis

POSITIVE FACTORS

  • MapLight Therapeutics is actively engaging with investors.
  • Participation in a prestigious healthcare conference enhances visibility.
  • The company is focused on addressing significant medical needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+154%
120-day peak, hindsight
Typical move
5.2%
average across 2 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
ML-007C-MA
Phase 2 · Schizophrenia

Full Press Release Details

SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:
Event: Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) Date: Monday, September 14 th Format: Presenting and hosting 1x1 meetings
Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. For more information, please visit www.maplightrx.com.

For investor inquiries: investors@maplightrx.com

For media inquiries: media@maplightrx.com

Frequently Asked Questions

When is MapLight Therapeutics participating in the conference?

MapLight Therapeutics will participate in the conference on September 14.

What is the format of the investor conference?

The format includes presentations and one-on-one meetings.

Where can I find the webcast of the event?

The webcast will be available on the company's Investor section of their website.

What is the focus of MapLight Therapeutics?

The company focuses on treatments for central nervous system disorders.

Last updated: Sep 9, 2026